News | August 07, 2024
Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Revolutionary technology will further boost OneSource’s scientific services offerings
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Subscribe To Our Newsletter & Stay Updated
